反饋

匡銘

鎖定

匡銘，男，畢業於中山醫科大學，現任中山大學附屬第一醫院副院長、腫瘤中心主任，中山大學中山醫學院院長。^[1] ^[12] 中山大學醫學部副主任、校長助理。^[16]

中文名: 匡銘
國籍: 中國
民族: 漢

畢業院校: 中山醫科大學
主要成就: 診斷治療肝臟腫瘤等疾病
職稱: 主任醫師，教授^[1]

匡銘人物簡介

匡銘，男，肝外科教授、腫瘤中心主任、博士生導師。國家傑出青年科學基金獲得者。^[2] 2022年12月，中山大學醫學部正式成立，匡銘教授被聘任為醫學部副主任。^[14]

匡銘職務任免

2024年1月23日消息，中山大學官網“現任領導”一欄更新，匡銘任校長助理。^[16]

匡銘研究方向

肝癌的消融治療、肝癌的免疫療法。

匡銘發表論文

(1) LX Xu, M.H. He, ZH Dai, J Yu, JG Wang, XC Li, BB Jiang, ZF Ke, TH Su, ZW Peng, Y Guo, ZB Chen, S.L. Chen, S Peng, M Kuang. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol, 2019^[4]

(2) Guo Y, Wu Z, Shen S, Guo R, Wang J, Wang W, Zhao K, Kuang M, Shuai X. Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy. Nat Commun, 2018, 9(1):3430.^[5]

(3) Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, Peng Z, Zhang Q, Peng S, Kuang M. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene, 2018, 37(26):3514-3527.^[6]

(4) Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, Shen YH, Cai JB, Yang Z, Zhou J, Fan J, Sun HC, Kuang M, Huang C. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. Journal of Hematology & Oncology, 2018, 11(1):28.^[7]

(5) Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, Chen M, Qian G,Kuang M. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology, 2018, 287(2):705-714.^[8]

(6) Jiang C, Long J, Liu B, Xu M, Wang W, Xie X, Wang X, Kuang M. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res, 2017, 36(1): 99.^[9]

(7) Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T, Tsung A, Tohme S, Huang H, Zhang Q, Lencioni R, Zeng Z, Peng B, Chen M, Kuang M. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. Cancer Lett, 2016, 373(2): 193-202.^[10]

(8) Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology, 2014, 60(4):1264-1277.^[11]